Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
USD 22.85
(1.78%)
USD 22.85
(1.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -218.84 Million USD | -25.56% |
| 2022 | -174.29 Million USD | -131.65% |
| 2021 | 550.66 Million USD | 197.73% |
| 2020 | 184.95 Million USD | 158.39% |
| 2019 | -316.72 Million USD | -115.85% |
| 2018 | -146.73 Million USD | -11.61% |
| 2017 | -131.46 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -153.97 Million USD | 29.64% |
| 2024 Q2 | -209.56 Million USD | -36.0% |
| 2023 Q1 | -95.27 Million USD | 45.34% |
| 2023 Q2 | -118.49 Million USD | -24.38% |
| 2023 Q3 | -80.13 Million USD | 32.38% |
| 2023 FY | -218.84 Million USD | -25.56% |
| 2023 Q4 | -218.84 Million USD | -173.11% |
| 2022 Q4 | -174.29 Million USD | -283.37% |
| 2022 Q3 | -45.46 Million USD | 82.06% |
| 2022 Q2 | -253.44 Million USD | -135.69% |
| 2022 Q1 | 710.16 Million USD | 28.97% |
| 2022 FY | -174.29 Million USD | -131.65% |
| 2021 FY | 550.66 Million USD | 197.73% |
| 2021 Q1 | 353.26 Million USD | 161.08% |
| 2021 Q4 | 550.66 Million USD | 367.23% |
| 2021 Q3 | 117.85 Million USD | 466.83% |
| 2021 Q2 | -32.12 Million USD | -109.09% |
| 2020 Q2 | -261.06 Million USD | 39.04% |
| 2020 FY | 184.95 Million USD | 158.39% |
| 2020 Q3 | -52.09 Million USD | 80.04% |
| 2020 Q1 | -428.23 Million USD | -35.21% |
| 2020 Q4 | 135.3 Million USD | 359.73% |
| 2019 Q2 | -465.73 Million USD | -114.22% |
| 2019 FY | -316.72 Million USD | -115.85% |
| 2019 Q4 | -316.72 Million USD | 23.97% |
| 2019 Q3 | -416.57 Million USD | 10.56% |
| 2019 Q1 | -217.4 Million USD | -48.16% |
| 2018 Q4 | -146.73 Million USD | 12.75% |
| 2018 Q2 | -217.45 Million USD | -108.68% |
| 2018 Q1 | -104.2 Million USD | 0.0% |
| 2018 FY | -146.73 Million USD | -11.61% |
| 2018 Q3 | -168.18 Million USD | 22.66% |
| 2017 Q1 | -47.19 Million USD | 0.0% |
| 2017 Q3 | -175.75 Million USD | 11.9% |
| 2017 Q2 | -199.5 Million USD | -322.72% |
| 2017 FY | -131.46 Million USD | 0.0% |
| 2017 Q4 | - USD | 100.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ADC Therapeutics SA | -154.22 Million USD | -41.902% |
| Alto Neuroscience, Inc. | 68.91 Million USD | 417.555% |
| Annovis Bio, Inc. | -5.75 Million USD | -3702.844% |
| Ginkgo Bioworks Holdings, Inc. | -707.09 Million USD | 69.05% |
| Nuvation Bio Inc. | -38.64 Million USD | -466.335% |
| Nuvation Bio Inc. | -38.64 Million USD | -466.335% |
| Arcus Biosciences, Inc. | -116 Million USD | -88.658% |
| Zymeworks Inc. | -130.83 Million USD | -67.266% |